Dr Steven O'Day speaks to ecancer about the phase 2 IMPRIME 1 study looking at the combination of pembrolizumab and a novel innate immune activator, Imprime PGG, in second-line, metastatic triple negative breast cancer (mTNBC).

He explains that Imprime PGG is a Beta Glucan agonist which is an innate activator of the immune system and by using this in addition to pembrolizumab the hope was that it would lead to a more robust immune response.

Dr O'Day reports that the results showed significant improvement on historical single agent activity, including a disease control rate beyond 6 months of 25% and a median survival of 16.4%.